.jpg)
This site uses cookies. By continuing to browse the site you are agreeing to our use of cookies.
Former HHS Secretary Donna Shalala writes that RFK Jr.’s reorganization is “sill...
STAT reporters discuss the layoffs and reorganization of HHS, data privacy conce...
Sen. Bill Cassidy says that health secretary RFK Jr. briefed him on his plans fo...
THURSDAY, March 27, 2025 -- Funding reductions could reverse progress in the HIV...
THURSDAY, March 27, 2025 -- Assessment of prostate-specific antigen (PSA) level ...
THURSDAY, March 27, 2025 -- A wearable T-shirt monitor can help oncological urol...
THURSDAY, March 27, 2025 -- Pelabresib, a bromodomain and extraterminal domain ...
THURSDAY, March 27, 2025 -- Parallel transmit (pTx) 7 Tesla (T) magnetic resona...
THURSDAY, March 27, 2025 -- Most comatose patients resuscitated from cardiac ar...
THURSDAY, March 27, 2025 -- Colorectal cancer (CRC) is tied to an increased risk...
THURSDAY, March 27, 2025 -- Automated deep learning-based quantification of brea...
In this edition of STAT's Health Tech newsletter: A closer look at the adoption ...
As part of an ongoing expansion strategy around the globe, Chiesi announced this...
Human medicines European public assessment report (EPAR): Laventair Ellipta (pre...
Human medicines European public assessment report (EPAR): Anoro Ellipta (previou...
Human medicines European public assessment report (EPAR): Respreeza, alpha1-prot...
Human medicines European public assessment report (EPAR): Zeposia, ozanimod, Dat...
Human medicines European public assessment report (EPAR): VeraSeal, human fibrin...
Among other functions, the NK cells (Natural Killers, a type of lymphocyte formi...
Scientists from Johns Hopkins Medicine and eight other institutions in the Unite...
Human medicines European public assessment report (EPAR): Yuflyma, adalimumab, D...
A former Pfizer-turned-GSK scientist reportedly told colleagues that Pfizer dela...
The FDA has approved Soleno Therapeutics' Vykat XR as the first treatment for in...
Human medicines European public assessment report (EPAR): Cresemba, isavuconazol...